Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Influenza A virus
0.01M PBS, pH 7.4.
>95% by SDS-PAGE.
Research Grade Diridavumab Biosimilar
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
CR-6261, CR6261, CAS: 1393659-46-5, Influenza Virus (Flu)
For research use only. Not suitable for clinical or therapeutic use.
武汉科斯坦生物科技有限公司 版权所有(C)2023 XML 技术支持： 食品商务网 盖德化工网